Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study)

Left Ventricular Dysfunction Clinical Trial

Official title:

A Phase II, Randomized, Controlled, Double-Blind Pilot Trial Evaluating the Safety and Effect of Administration of Bone Marrow Mononuclear Cells Two to Three Weeks Following Acute Myocardial Infarction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00684060
• Other study ID #: 578
• Secondary ID: 1U01HL0873181 U0
• Status: Completed
• Phase: Phase 2
• First received: May 22, 2008
• Last updated: July 7, 2015
• Start date: July 2008
• Est. completion date: February 2012

Study information

• Verified date: July 2015
• Source: The University of Texas Health Science Center, Houston
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

More than 1 million Americans suffer heart attacks each year. Although current treatments are able to stabilize the condition of the heart, none is able to restore heart function as it was prior to the heart attack. Adult stem cells, which are immature cells that can become many different types of cells, may offer a potential means of reversing or preventing permanent damage caused by a heart attack. Recent studies have shown promise in using adult stem cells from bone marrow to reverse damage to the heart muscle caused by a heart attack, but more research is needed to assess the safety and effectiveness of stem cell use and to discover the best time to administer treatment. This study will evaluate the safety and effectiveness of using adult stem cell infusions 2 to 3 weeks after a heart attack for improving heart function in people who have had a recent heart attack and a common procedure called a percutaneous coronary intervention (PCI).

Description:

Heart attacks are a leading cause of death for both men and women in the United States. A heart attack occurs when blood flow to the heart is restricted, commonly due to a blood clot that has formed in one of the coronary arteries. If the clot becomes large enough, blood flow to the heart can be blocked almost completely and the heart muscle in that area can suffer permanent injury or death. Although a PCI can be used to open up the blocked artery and restore blood flow to the heart muscle, there may be a significant amount of heart tissue that has been irreversibly damaged. Recent studies have shown that adult stem cells from bone marrow may be able to improve heart function after a heart attack. These specialized cells may have the ability to promote blood vessel growth, prevent cell death, and transform themselves into a number of tissues, including muscle. After an acute heart attack, a remodeling process is initiated in the heart in an attempt to compensate for damaged areas. Consequently, the condition of the heart muscle several weeks after a heart attack may differ considerably from the heart's condition during the acute setting. For some patients, delaying the delivery of the stem cells until 2 to 3 weeks after a heart attack may be better than initiating treatment during the acute phase. This study will evaluate the safety and effectiveness of placing adult stem cells into injured heart muscle 2 to 3 weeks after a heart attack for improving heart function in people who have had a recent heart attack and a PCI.

Participation in this study will last 24 months. All participants will first undergo baseline assessments that will include a medical history, a physical exam, an electrocardiogram (ECG), blood draws, an echocardiogram, and a magnetic resonance imaging (MRI) test. Participants will then be assigned randomly to receive stem cells or placebo between 2 and 3 weeks after their heart attack. The morning of the stem cell or placebo infusion, participants will undergo a blood draw and a bone marrow aspiration procedure of the hip bone to collect the stem cells. Later the same day, either stem cells or placebo will be infused through a catheter and into the damaged area of the heart.

For the first 24 hours after the infusion, participants will be asked to wear a small ECG machine called a Holter monitor. Participants will also be asked to record their temperature twice a day for a month after the infusion. Participants will return for follow-up visits at Months 1, 3, 6, 12, and 24 and will repeat many of the baseline assessments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: February 2012
• Est. primary completion date: August 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 21 Years and older

Eligibility

Inclusion criteria

1. Patients at least 21 years of age.

2. Patients with first acute MI and subsequent successful primary percutaneous coronary intervention (PCI) in an artery at least 2.5 mm in diameter occurring two to three weeks before recruitment.

3. No contraindications to undergoing cell therapy procedure within two to three weeks following AMI and PCI.

4. Hemodynamic stability as defined as no requirement for IABP, inotropic or blood pressure supporting medications.

5. Ejection fraction following reperfusion with PCI <=45% as assessed by echocardiography.

6. Consent to protocol and agree to comply with all follow-up visits and studies.

7. Women of child bearing potential willing to use an active form of birth control.

Exclusion criteria

Patients will be excluded from the study if they meet any of the following conditions:

1. History of sustained ventricular arrhythmias not related to their AMI (evidenced by previous holter monitoring and/or medication history for sustained ventricular arrhythmias in patient's medical chart).

2. Require CABG or PCI due to the presence of residual coronary stenosis >70% luminal obstruction in the non-infarct related vessel (Additional PCI of non-culprit vessels may be performed prior to enrollment).

3. History of any malignancy within the past five years excluding non-melanoma skin cancer or cervical cancer in-situ.

4. History of chronic anemia (hemoglobin (Hb) <9.0 mg/dl).

5. History of thrombocytosis (platelets >500k).

6. History of thrombocytopenia in the absence of recent evidence that platelet counts are normal

7. Known history of elevated INR (PT) or PTT.

8. Life expectancy less than one year.

9. History of untreated alcohol or drug abuse.

10. Currently enrolled in another Investigational drug or device trial

11. Previous CABG.

12. Previous MI resulting in LV dysfunction (LVEF <55%)

13. History of stroke or transient ischemic attack (TIA) within the past six months.

14. History of severe valvular heart disease (aortic valve area <1.0 cm2 or >3+ mitral regurgitation).

15. Pregnancy or breast feeding

16. Subjects with a known history of HIV, or has active hepatitis B, active hepatitis C, or active tuberculosis (TB)

17. Patients with active inflammatory or autoimmune disease on chronic immunosuppressive therapy.

18. Contraindications to cMRI.

19. Previous radiation to the pelvis with white blood cell count (WBC) and platelet counts below hospital specific normal values.

20. Women child bearing potential not willing to practice an active form of birth control.

21. Chronic liver disease that might interfere with survival or treatment with cell therapy.

22. Chronic renal insufficiency as defined by a creatinine =2.0 mg/dL or requires chronic dialysis.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Left Ventricular Dysfunction
• Myocardial Infarction
• Ventricular Dysfunction
• Ventricular Dysfunction, Left

Intervention

Biological:
• Adult stem cells
One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
• Placebo
One time infusion of 30 ml of HSA (5%)

Locations

Country	Name	City	State
United States	Cleveland Clinic	Cleveland	Ohio
United States	University of Florida - Department of Medicine	Gainesville	Florida
United States	Texas Heart Institute	Houston	Texas
United States	Minneapolis Heart Institute Foundation	Minneapolis	Minnesota
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

References & Publications (4)

Gee AP, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. Cytotherapy. 2010 Sep;12(5):684-91. doi: 10.3109/14653249.2010.487900. — View Citation

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, J — View Citation

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37(4):412-20. — View Citation

Zierold C, Carlson MA, Obodo UC, Wise E, Piazza VA, Meeks MW, Vojvodic RW, Baraniuk S, Henry TD, Gee AP, Ellis SG, Moyé LA, Pepine CJ, Cogle CR, Taylor DA. Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. Am Heart J. 2011 Dec;162(6):973-80. doi: 10.1016/j.ahj.2011.05.024. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global Left Ventricular Function	Left ventricular ejection fraction (global) as assessed via cardiac MRI. Values reported represent the change in Global EF from baseline to six months.	Measured at Baseline and Month 6	No
Primary	Regional Left Ventricular Function (Infarct Zone Wall Motion)	One of two calculated values of regional left ventricular function as assessed via cardiac MRI. The infarct zone is defined as the cMRI segments with the largest 2 signal intensity enhancement measures with gadolinium (using a 17-segment model).Values reported represent the change in wall motion over time in the infarct zone from baseline to six months.	Measured at Baseline and Month 6	No
Primary	Regional Left Ventricular Function (Border Zone Wall Motion)	Two of two calculated values of regional left ventricular function assessed via cardiac MRI. The border zone is defined as those regions adjacent to the infarct zone in which the cMRI signal intensity enhancement were in the 10%-75% range. Values reported represent the change in wall motion over time in the border zone of the infarct from baseline to six months.	Measured at Baseline and Month 6	No
Secondary	Combined Endpoint	Combined endpoint: first of death, reinfarction, repeat revascularization, and hospitalization for heart failure. This is measured as the number of events by treatment group over the 6 month follow up period.	Measured at Baseline and Month 6	Yes
Secondary	Left Ventricular Mass	Left ventricular mass (LV mass. Values reported represent the change in LV mass from baseline to six months.)	Measured at Baseline and Month 6	No
Secondary	End Diastolic Volume Index	Left ventricular end diastolic volume index. Values reported represent the change in LV end diastolic index from baseline to six months.	Measured at Baseline and Month 6	No
Secondary	End Systolic Volume Index	Left ventricular end systolic volume index. Values reported represent the change in LV end systolic volume index from baseline to six months.	Measured at Baseline and Month 6	No
Secondary	Infarct Volume	Infarct volume(mL). Values reported represent the change in infarct volume from baseline to six months.	Measured at Baseline and Month 6	No

External Links

•   Click here for more information on stem cells at the National Institutes of Health Stem Cell Basics
•   Click here for more information on this study at the Cardiovascular Cell Therapy Research Network (CCTRN)
•   Click here for more information on this study at the Indiana Center for Vascular Biology and Medicine
•   Click here for the National Heart, Lung, and Blood Institute